Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis.

PLoS Pathog

Department of Microbiology and Immunology, Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago, Illinois, United States of America.

Published: February 2010

Differentiation, distribution and immune regulation of human IL-22-producing T cells in infections remain unknown. Here, we demonstrated in a nonhuman primate model that M. tuberculosis infection resulted in apparent increases in numbers of T cells capable of producing IL-22 de novo without in vitro Ag stimulation, and drove distribution of these cells more dramatically in lungs than in blood and lymphoid tissues. Consistently, IL-22-producing T cells were visualized in situ in lung tuberculosis (TB) granulomas by confocal microscopy and immunohistochemistry, indicating that mature IL-22-producing T cells were present in TB granuloma. Surprisingly, phosphoantigen HMBPP activation of Vgamma2Vdelta2 T cells down-regulated the capability of T cells to produce IL-22 de novo in lymphocytes from blood, lung/BAL fluid, spleen and lymph node. Up-regulation of IFNgamma-producing Vgamma2Vdelta2 T effector cells after HMBPP stimulation coincided with the down-regulated capacity of these T cells to produce IL-22 de novo. Importantly, anti-IFNgamma neutralizing Ab treatment reversed the HMBPP-mediated down-regulation effect on IL-22-producing T cells, suggesting that Vgamma2Vdelta2 T-cell-driven IFNgamma-networking function was the mechanism underlying the HMBPP-mediated down-regulation of the capability of T cells to produce IL-22. These novel findings raise the possibility to ultimately investigate the function of IL-22 producing T cells and to target Vgamma2Vdelta2 T cells for balancing potentially hyper-activating IL-22-producing T cells in severe TB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829073PMC
http://dx.doi.org/10.1371/journal.ppat.1000789DOI Listing

Publication Analysis

Top Keywords

il-22-producing cells
24
cells
15
il-22 novo
12
cells produce
12
produce il-22
12
differentiation distribution
8
vgamma2vdelta2 cells
8
capability cells
8
hmbpp-mediated down-regulation
8
il-22-producing
6

Similar Publications

Type 3 Innate lymphoid cells (ILC3s) functions bear complex response during Inflammatory bowel diseases (IBD). Here, our study first analyzed the main pharmacological components in Shen Ling Bai Zhu San n-butanol extracts (S-Nb), and then explored whether S-Nb administrated immune response of ILC3s, and how it regulates ILC3s. Shen Ling Bai Zhu San (SLBZS) or S-Nb were administrated for 7 days to analyze the frequency of ILC3s and their produced cytokine.

View Article and Find Full Text PDF
Article Synopsis
  • Blocking IL-13 is effective for treating atopic dermatitis (AD), and new research suggests that targeting T cell costimulatory molecules like OX40 and OX40L could also be a beneficial treatment option.
  • This study investigates whether targeting CD30L might be an additional therapeutic avenue, by comparing it with existing targets like IL-13 and OX40L using single-cell RNA-seq and a murine model of AD.
  • Results showed that blocking CD30L effectively reduced disease symptoms in mice, indicating that targeting the CD30-CD30L pathway could be a promising future treatment for human atopic dermatitis, similar to targeting the OX40-OX40L pathway.
View Article and Find Full Text PDF
Article Synopsis
  • Enhanced mortality and relapse rates of Clostridioides difficile infection (CDI) highlight the urgent need for improved therapies, as current antibiotic options are insufficient.
  • Researchers found that progranulin (PGRN) plays a key role in immune response during CDI, with PGRN-deficient mice showing higher mortality and more intestinal damage despite similar infection levels.
  • PGRN protects against CDI by promoting the production of IL-22 from CD4 T helper cells, suggesting that targeting the host's immune response could offer a new strategy for treating severe CDI cases.
View Article and Find Full Text PDF

Introduction: Colitis is an inflammatory bowel disease (IBD) characterized by immune cell dysregulation and alterations in the gut microbiome. In our previous report, we showed a natural product in cruciferous vegetables and ligand of the aryl hydrocarbon receptor (AhR), indole-3-carbinol (I3C), was able to reduce colitis-induced disease severity and microbial dysbiosis in an interleukin-22 (IL-22) dependent manner.

Methods: In the current study, we performed single-cell RNA sequencing (scRNAseq) from colonocytes during colitis induction and supplementation with I3C and show how this treatment alters expression of genes involved in IL-22 signaling.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!